Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
Status:
Terminated
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose for this study (CY 1124) is to evaluate the effects of CK-1827452, a cardiac
myosin activator, on myocardial systolic performance, myocardial oxygen consumption, and
myocardial efficiency in patients with heart failure and to confirm that the unique
preclinical pharmacological profile of CK- 1827452 is substantially the same in patients with
heart failure.